Jove
Visualize
Contact Us

Related Concept Videos

Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

5.3K
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
5.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Urachal adenocarcinoma: Case report, literature review, and therapeutic algorithm proposal.

Actas urologicas espanolas·2026
Same author

[Effect of a Health Education intervention on self-esteem in adolescents].

Semergen·2025
Same author

Neuroinmunological diseases in paediatric patients: New entities and update.

Radiologia·2025
Same author

Occupational Rhinoconjunctivitis Induced by Unusual Allergens of Carrot.

Journal of investigational allergology & clinical immunology·2020
Same author

Safety of nivolumab in metastatic renal cell carcinoma patients: A real-life experience in a Spanish urology setting.

Actas urologicas espanolas·2019
Same author

[Chest ultrasonography in pleurapulmonary disease].

Radiologia·2012
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Mar 3, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

14.0K

Incidental Leydig Cell Tumor in Patient with Hormone Resistant Prostate Cancer.

M Sánchez Pérez1, P Jiménez Marrero1, D Kim Lee1

  • 1Servicio de Urología HUGCDN Barranco de la Ballena s/n Las Palmas de Gran Canaria, Spain.

Urology Case Reports
|April 27, 2017
PubMed
Summary

A high-risk prostate cancer patient developed bone metastases despite treatment. An incidental Leydig cell tumor was discovered during orchiectomy after hormone therapies failed to control PSA levels.

Keywords:
Androgen deprivation therapyLeydig cellLeydig tumorOrchiectomyProstate cancer

More Related Videos

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

953
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.8K

Related Experiment Videos

Last Updated: Mar 3, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

14.0K
A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

953
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.8K

Area of Science:

  • Urology
  • Oncology
  • Endocrinology

Background:

  • High-risk prostate cancer (Gleason 9) necessitates aggressive treatment strategies.
  • Androgen deprivation therapy (ADT) and radiotherapy are standard initial treatments.
  • Prostate-specific antigen (PSA) progression indicates treatment resistance or recurrence.

Observation:

  • A 55-year-old male with T2bN1M0 high-risk prostate cancer showed resistance to ADT and radiotherapy.
  • Bone metastases and rising PSA levels were observed despite multiple hormonal therapies.
  • Bilateral orchiectomy was performed due to lack of response to previous treatments.

Findings:

  • Castration levels were not achieved with initial ADT.
  • Surgical castration via bilateral orchiectomy was performed.
  • Pathology revealed an incidental Leydig cell tumor in the resected right testicle.

Implications:

  • The incidental Leydig cell tumor may have contributed to treatment resistance.
  • This case highlights the importance of thorough histopathological examination, even in incidental findings.
  • Further investigation into Leydig cell tumors in the context of treatment-refractory prostate cancer is warranted.